Customized managed access programs designed for rare disease therapies, guided by real world experience.
Does your rare disease commercial strategy need Managed Access expertise to guide your expansion planning?
RareiTi- a different kind of managed access company.
previous arrow
next arrow

Our advisory practice offers business advice and recommendations on the suitability, design and business impact of Managed Access programs for patients with rare diseases.

We deliver customized global Managed Access Programs designed to meet complex challenges for patients with a rare disease at the point of care.

RareiTi DATA provides the baseline of our strategic customizable analytics platform to accurately capture real-world patient experiences that measure patient outcomes.

Latest from RareiTi VIEW

Managed Access: A Solution with Benefits for Everyone

Managed access programs – also known as compassionate use, early access, and named-patient programs- have clear benefits for patients and physicians. These programs provide an alternative regulatory pathway to help patients access potentially life-altering drugs when they are ineligible for clinical trials or the drug has not been approved in their home country.   Historically, the…

Read More

Latest Tweets @RareiTi

An experienced senior leadership team

40+ rare disease conditions

50+ biotech and pharma companies

200+ managed access programs

100,000s of patients supported with access to treatment

COVID-19 Response

The COVID-19 pandemic is having significant impact on clinical trials globally. Many trials face suspension or closure due to clinical priorities and the impact of social distancing and quarantine.

Clinical trial patients with a rare condition face great challenges; being part of a clinical trial when living with a rare condition can often be the only lifeline available, offering the chance to access novel therapies that could improve life enormously. During the pandemic, not being able to access novel therapies could have a major negative impact on health, disease progression and mortality. In addition, progress toward an approved therapy should not have to be completely stalled because of a lack of ability to collect relevant data.

Privacy Policy

RareiTi™ needs to collect and process personal information in order to deliver services that provide medicines and support under regulated activities. We run joint programmes with our patient’s referring physician/centres and the pharmaceutical manufacturers as part of our pharmacovigilance and drug safety obligations.  We also participate in highly regulated activities that require the sharing of your data for clinical evidence purposes outside of a clinical trial.

We are committed to being transparent with you about our use of your personal information.  We will always keep your data safe and secure and only use it for the purposes it was obtained. We will ensure we record the lawful grounds for the use of your data and keep you informed of any changes.


Our website uses cookies. When those cookies are not strictly necessary for the provision of RareiTi website and services, we will ask you to consent to our use of cookies when you first visit our website.

We use cookies for the following purposes:

  • authentication – we use cookies to identify you when you visit our website and as you navigate our website
  • analysis – we use cookies to help us to analyze the use and performance of our website and services

Managing cookies
Most browsers allow you to refuse to accept cookies and to delete cookies. The methods for doing so vary from browser to browser, and from version to version. You can however obtain up-to-date information about blocking and deleting cookies via these links:

(a) (Chrome);(b) (Firefox);(c) (Opera);(d) (Internet Explorer);(e) (Safari); and
(f) (Edge).

Blocking all cookies will have a negative impact upon the usability of many websites.

Follow us on:


London  •  Chicago  •  New Jersey

©2020 RareiTi